Comparison of sodium bicarbonate capsules and gastro-resistant sodium bicarbonate tablets in patients with stage 4 chronic kidney disease

Abstract

Objective: In this study, we aimed to compare stage 4 chronic kidney disease patients who received sodium bicarbonate treatment in the form of 500 mg capsules and 1000 mg gastro-resistant tablets. Methods: All patients with stage 4 chronic kidney disease presenting to the nephrology clinic between August 2020 and November 2020 were evaluated retrospectively. The patients were divided into 2 groups: sodium bicarbonate group and gastro-resistant sodium bicarbonate group. Groups were compared in terms of serum bicarbonate and side effects during follow-up. Results: A total of 43 stage 4 chronic kidney disease patients were included in this study. The bicarbonate change in both groups was statistically significant after the first week (P < .001). In the gastro-resistant sodium bicarbonate group bicarbonate level was significantly higher than the sodium bicarbonate group in the first week (P < .001). Conclusions: Gastro-resistant sodium bicarbonate seems to normalize serum sodium bicarbonate earlier than sodium bicarbonate.